Trial Profile
A Phase I Study of Allogeneic NK Cell Therapy in Patients With Refractory/Relapsed Lymphoma or Solid Tumor
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs MG 4101 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- 28 Feb 2014 New trial record